A Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)
Status:
Completed
Trial end date:
2019-01-28
Target enrollment:
Participant gender:
Summary
Ibrutinib is currently FDA approved and commercially available for the treatment of CLL.
However, some researchers think the approved dose may be unnecessarily high.
The goal of this clinical research study is to compare 3 different daily doses of ibrutinib
to learn how these doses affect the disease and your body. Researchers think that if a lower
dose of ibrutinib can be found to be as effective as the currently approved dose this may
help to lower the risk of side effects.